Comparing different acellular dermal matrices for breast reconstruction
Official title: The BREAST Trial: A Randomized, Non-inferiority, Study Comparing the Complication Profile of Four Commercially Available Acellular Dermal Matrixes Used in Alloplastic Breast Reconstruction
Run by University of British Columbia · NCT04661501 · Data updated 2026-11-12
This study is testing which of four different materials used in breast reconstruction helps prevent fluid buildup after surgery in women undergoing this procedure.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 21 Years to 65 Years |
| Sex | Women only |
| Enrollment | 328 (estimated) |
| Sponsor | University of British Columbia Academic / other |
| Drugs / interventions | radiation |
| Locations | 4 sites (Vancouver, British Columbia and 3 other locations) |
| Status | Recruiting |
| Started | November 25, 2020 |
| Main results expected | December 31, 2025 |
| Study ends | December 31, 2025 |
| Registry record updated | December 16, 2024 |
| Trial ID | NCT04661501 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are women aged 21 to 65 undergoing unilateral or bilateral mastectomy with plans for alloplastic breast reconstruction using ADM.
✕Probably not a fit
Patients undergoing autologous reconstruction or those with contraindications to the ADMs will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial is a randomized single-blinded prospective study that evaluates the surgical outcomes of four different acellular dermal matrices (ADMs) used in alloplastic breast reconstruction. Participants will be randomly assigned to receive one of the four ADMs: AlloDerm, AlloMax, DermACELL, or Flex HD, during a two-stage reconstruction process involving tissue expanders. The primary focus is to compare the incidence of clinically significant post-operative seromas requiring intervention over a two-year follow-up period. The trial will begin with a pilot phase targeting 40 patients to assess feasibility and establish necessary protocols.
Why it matters
Potential benefit: If successful, this study could help identify the most effective ADM for breast reconstruction, potentially reducing complications and improving patient outcomes.
How similar studies have gone: While this approach is being tested in this specific context, previous studies have shown varying outcomes with different ADMs, indicating that this comparison could provide valuable insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * All woman aged 21 years or older but less that 65 undergoing unilateral or bilateral mastectomy with alloplastic breast reconstruction using ADM. * Breast reconstruction must be done by means of a two staged process using tissue expanders and ADM based reconstruction followed by implant tissue expander to implant exchange. Exclusion Criteria: * Patients undergoing autologous reconstruction either at the time of mastectomy or in a delayed fashion. * Patients with a history of previous breast reconstruction procedures. * Patients with prior radiation treatment to the breast or with prior mantle radiation * Any patient with a contraindication to breast reconstruction * Patients undergoing an axillary node dissection with clearance * Patients with an allergy to Polysporin or any of its ingredients. * Patients with contraindications to any of the acellular dermal matrices: • DermACELL: Allergy to Gentamicin, Vancomycin\[12\] * The surgeon performing the breast reconstruction may also deem a patient ineligible if intraoperatively, there is evidence of significant mastectomy flap ischemia prior to the initiation of the breast reconstruction procedure.
Where it's running
-
Mount Saint Joseph's Hospital
Vancouver, British Columbia, Canada Recruiting -
Vancouver General Hospital
Vancouver, British Columbia, Canada Recruiting -
UBC Hospital
Vancouver, British Columbia, Canada Recruiting -
Saint Paul's Hospital
Vancouver, British Columbia, Canada Recruiting
Study contacts
- Principal investigator: Dr. Nancy Van Laeken — University of British Columbia
- Study coordinator: Dr. Nancy Van Laeken
- Email: nancy@vanlaeken.com
- Phone: 604-669-1633
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ESP Blocks to Help Pain After Breast Reconstruction with Autologous Flaps
This study tests whether erector spinae plane blocks can improve pain control after autologous free flap breast reconstruction in adults.
-
EndoBreast: Feasibility and outcomes of nipple-sparing endoscopic mastectomy with immediate reconstruction
This observational study tests whether endoscopic nipple-sparing mastectomy with immediate reconstruction is feasible and acceptable for women at risk or with breast cancer.
-
Access My Breast Cancer Care App
A breast cancer care app is being tested to see if it helps patients navigate care, feel more satisfied, and reduce in-person visits.
-
Breast implant study to see how Luna implants perform after surgery
This study tests whether Eurosilicone Luna breast implants stay intact and keep their shape over 10 years in women aged 18–65 undergoing cosmetic or reconstructive breast surgery.
-
Autologous Fat Grafting vs DIEP flap for reconstructed breast after radiation
This study tests whether autologous fat transfer can provide similar satisfaction and safety to the DIEP flap procedure for women needing breast reconstruction after mastectomy and radiation.
-
Prehabilitation with physiotherapy and mechanical stimulation before LD flap breast reconstruction
This study tests whether prehabilitation with physiotherapy and mechanostimulation improves shoulder pain and mobility for women undergoing breast reconstruction with a latissimus dorsi flap.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.